Literature DB >> 24944044

Use of hyaluronidase for pharmacokinetic increase in bioavailability of intracutaneously applied substances.

Johannes Wohlrab1, David Wohlrab, Lukas Wohlrab, Christiane Wohlrab, Angelika Wohlrab.   

Abstract

Endogenous hyaluronidases in the human body have physiological and pathophysiological significance due to their enzymatic activity during the cleavage of hyaluronan. The potential of therapeutic use of testicular and recombinant hyaluronidase has been increasingly acknowledged and developed in recent years. Most relevant in practice is the co-application of hyaluronidase and other active substances in order to enhance their bioavailability within the tissue.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24944044     DOI: 10.1159/000360545

Source DB:  PubMed          Journal:  Skin Pharmacol Physiol        ISSN: 1660-5527            Impact factor:   3.479


  6 in total

1.  A neoteric multidrug combination: novel approach to limited cutaneous systemic scleroderma involving the face.

Authors:  M Hari Kumar; M Siva Kumar; Sabitha Hari Kumar; Kingsly Selva Kumar
Journal:  BMJ Case Rep       Date:  2016-03-31

Review 2.  Clinical Applications of Hyaluronidase.

Authors:  Gregor Cornelius Weber; Bettina Alexandra Buhren; Holger Schrumpf; Johannes Wohlrab; Peter Arne Gerber
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 3.  Hyaluronidase: from clinical applications to molecular and cellular mechanisms.

Authors:  Bettina Alexandra Buhren; Holger Schrumpf; Norman-Philipp Hoff; Edwin Bölke; Said Hilton; Peter Arne Gerber
Journal:  Eur J Med Res       Date:  2016-02-13       Impact factor: 2.175

4.  A Consensus on Minimizing the Risk of Hyaluronic Acid Embolic Visual Loss and Suggestions for Immediate Bedside Management.

Authors:  Greg J Goodman; Mark R Magnusson; Peter Callan; Stefania Roberts; Sarah Hart; Cara B McDonald; Michael Clague; Alice Rudd; Philip S Bekhor; Steven Liew; Michael Molton; Katy Wallace; Niamh Corduff; Sean Arendse; Shobhan Manoharan; Ava Shamban; Izolda Heydenrych; Ashish C Bhatia; Peter Peng; Tatjana Pavicic; Krishan Mohan Kapoor; David E Kosenko
Journal:  Aesthet Surg J       Date:  2020-08-14       Impact factor: 4.283

Review 5.  Nanoparticle-based delivery systems modulate the tumor microenvironment in pancreatic cancer for enhanced therapy.

Authors:  Ming Jia; Dan Zhang; Chunxiang Zhang; Chunhong Li
Journal:  J Nanobiotechnology       Date:  2021-11-22       Impact factor: 10.435

Review 6.  Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma.

Authors:  Hui Yan; Bo Zhai; Fang Yang; Zhenliang Chen; Qiang Zhou; Ana Cláudia Paiva-Santos; Ziqiao Yuan; Yang Zhou
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.